Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to -$3.4 million.

  • HCW Biologics' Income towards Parent Company rose 1263.29% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.7 million, marking a year-over-year increase of 6599.53%. This contributed to the annual value of -$30.1 million for FY2024, which is 1580.99% down from last year.
  • HCW Biologics' Income towards Parent Company amounted to -$3.4 million in Q3 2025, which was up 1263.29% from -$3.7 million recorded in Q2 2025.
  • HCW Biologics' 5-year Income towards Parent Company high stood at -$1.9 million for Q1 2022, and its period low was -$15.3 million during Q2 2024.
  • Over the past 5 years, HCW Biologics' median Income towards Parent Company value was -$3.9 million (recorded in 2024), while the average stood at -$4.9 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 23207.9% in 2024, then surged by 7585.73% in 2025.
  • Over the past 5 years, HCW Biologics' Income towards Parent Company (Quarter) stood at -$3.1 million in 2021, then tumbled by 85.12% to -$5.8 million in 2022, then crashed by 86.87% to -$10.8 million in 2023, then soared by 68.35% to -$3.4 million in 2024, then decreased by 0.33% to -$3.4 million in 2025.
  • Its Income towards Parent Company stands at -$3.4 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$2.2 million for Q1 2025.